홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

(1R,2S,3R,5S)-3-[2-((R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-5-(5-ethyl-tetrazol-2-yl)-cyclopentane-1,2-diol → 1-((R)-1-{6-(2,2-Diphenyl-ethylamino)-9-[(1R,2S,3R,4S)-4-(5-ethyl-tetrazol-2-yl)-2,3-dihydroxy-cyclopentyl]-9H-purin-2-yl}-pyrrolidin-3-yl)-3-pyridin-3-yl-urea

HRID 1641938
인쇄

반응식

HRID 1641938 반응식
N[C@@H]1CCN(C2N=C3C(N=CN3[C@@H]3C[C@H](N4N=NC(CC)=N4)[C@@H](O)[C@H]3O)=C(NCC(C3C=CC=CC=3)C3C=CC=CC=3)N=2)C1.Cl.[C:46]1([CH:52]([C:93]2[CH:98]=[CH:97][CH:96]=[CH:95][CH:94]=2)[CH2:53][NH:54][C:55]2[N:63]=[C:62]([N:64]3[CH2:68][CH2:67][C@@H:66]([NH:69][C:70]([NH:72][C:73]4[CH:74]=[N:75][CH:76]=[CH:77][CH:78]=4)=[O:71])[CH2:65]3)[N:61]=[C:60]3[C:56]=2[N:57]=[CH:58][N:59]3[C@@H:79]2[CH2:83][C@H:82]([N:84]3[N:88]=[N:87][C:86]([CH2:89][CH3:90])=[N:85]3)[C@@H:81]([OH:91])[C@H:80]2[OH:92])[CH:51]=[CH:50][CH:49]=[CH:48][CH:47]=1>>[C:93]1([CH:52]([C:46]2[CH:47]=[CH:48][CH:49]=[CH:50][CH:51]=2)[CH2:53][NH:54][C:55]2[N:63]=[C:62]([N:64]3[CH2:68][CH2:67][C@@H:66]([NH:69][C:70]([NH:72][C:73]4[CH:74]=[N:75][CH:76]=[CH:77][CH:78]=4)=[O:71])[CH2:65]3)[N:61]=[C:60]3[C:56]=2[N:57]=[CH:58][N:59]3[C@@H:79]2[CH2:83][C@H:82]([N:84]3[N:88]=[N:87][C:86]([CH2:89][CH3:90])=[N:85]3)[C@@H:81]([OH:91])[C@H:80]2[OH:92])[CH:98]=[CH:97][CH:96]=[CH:95][CH:94]=1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

3

반응물 2

HCID 11650095(1R,2S,3R,5S)-3-[2-((R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-5-(5-ethyl-tetrazol-2-yl)-cyclopentane-1,2-diolHCID 667359671-((R)-1-{6-(2,2-Diphenyl-ethylamino)-9-[(1R,2S,3R,4S)-4-(5-ethyl-tetrazol-2-yl)-2,3-dihydroxy-cyclopentyl]-9H-purin-2-yl}-pyrrolidin-3-yl)-3-pyridin-3-yl-urea hydrochloride

생성물 1

HCID 667357771-((R)-1-{6-(2,2-Diphenyl-ethylamino)-9-[(1R,2S,3R,4S)-4-(5-ethyl-tetrazol-2-yl)-2,3-dihydroxy-cyclopentyl]-9H-purin-2-yl}-pyrrolidin-3-yl)-3-pyridin-3-yl-urea

실험 절차

This compound is prepared from (1R,2S,3R,5S)-3-[2-((R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-5-(5-ethyl-tetrazol-2-yl)-cyclopentane-1,2-diol (Example 48), using a procedure analogues to that of 1-((R)-1-{6-(2,2-diphenyl-ethylamino)-9-[((1R,2S,3R,4S)-4-(5-ethyl-tetrazol-2-yl)-2,3-dihydroxy-cyclopentyl]-9H-purin-2-yl}-pyrrolidin-3-yl)-3-pyridin-3-yl-urea hydrochloride (Example 104). After purification, the compound is partitioned between DCM and saturated NaHCO3 (aq). The organics are dried (MgSO4), filtered and reduced in vacuo to yield the title compound. MS (ES+) m/e 716.51 (MH+).

후처리

  1. customAfter purification
  2. customthe compound is partitioned between DCM and saturated NaHCO3 (aq)
  3. dry with materialThe organics are dried (MgSO4)
  4. filtrationfiltered

출처 및 근거

ORD 기록
ord-478ae855e1884d1da2e2b4aa48445726
출처 데이터셋
uspto-grants-2012_02
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08114877B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트